Saturday 17 October 2026 Export BVS’s income statement to Excel — free account

Bioventus Inc.

Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

13.30 0.51 −3.69%

Follow BVS

Alert me

Market cap: $1.2B
P/E: 16.4×
Fwd P/E: 21.4×
Dividend yield: —
F-score: 8/9
Altman Z: 1.26
Beneish M: −2.77
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.31

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	—	—	1	—	—	—	—	—	—	—

Insider Ownership 30.38%

Capital & Financial Ratios $m

Market Cap 1,160.00

Revenue 581.85

Net Income 61.48

Free Cash Flow 94.29

Net Debt 219.00

Current Ratio 1.69

Debt/Equity 0.90

P/E ratio 16.42

Fwd P/E 21.40

P/S ratio 1.55

P/B ratio 3.25

Past 5Y EPS Growth (18.00%)

This Y EPS Growth 14.54%

Next Y EPS Growth 18.17%

Next Y revenue growth (26.07%)

Next 5Y EPS Growth 16.02%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 84.72%

10-year low 10-year high

P/B against its own 10 years 84.93%

10-year low 10-year high

EV/Sales against its own 10 years 80.17%

10-year low 10-year high

EV/FCF against its own 10 years 15.43%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	37	42	51	29
Receivables	123	127	128	138
Inventory	91	92	82	80
Other	—	—	—	—
	268	276	273	258

	2023	2024	2025	Q'26
Payables	23	24	11	20
ST’ Debt	28	27	15	19
Other	5	23	4	4
	175	210	160	152

Compound Annual Growth %

	10y	5y	3y
Sales	—	12.08%	3.52%
Cash Flow	—	0.79%	0.00%
Earnings	—	6.73%	0.00%
Book Value	—	9.64%	(17.86%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	132	153	—	—	—
’25	124	148	139	158	568
’24	129	151	139	154	573
’23	119	137	121	135	512
’22	117	140	129	126	512
’21	82	110	109	130	431
’20	79	58	86	99	321

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	9	20	—	—	—
’25	(19)	26	30	38	75
’24	(6)	15	10	19	39
’23	2	11	(8)	10	15
’22	(21)	3	(1)	5	(14)
’21	(18)	17	11	13	23
’20	18	8	21	25	72

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	8	19	—	—	—
’25	(20)	25	30	37	72
’24	(6)	15	10	19	38
’23	(1)	9	(10)	10	8
’22	(24)	1	(2)	10	(15)
’21	(19)	16	9	4	9
’20	17	7	20	24	55

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.04	0.47	—	—	—
’25	(0.04)	0.11	0.05	0.21	0.33
’24	(0.07)	(0.37)	(0.07)	0.00	(0.52)
’23	(2.24)	(0.06)	(0.12)	(0.10)	(2.49)
’22	(0.19)	(0.11)	(1.76)	(0.52)	(2.59)
’21	0.59	(0.10)	(0.03)	(0.01)	(0.15)
’20	0.19	—	0.05	0.57	0.89

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	10.74	1.65	0.80	3.90	5.81	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	19.94	15.57	5.54	14.38	11.25
People
People	Employees	—	—	—	680	700	1,200	1,120	970	930	930
	Revenue/emp, $m	0.00	0.00	0.00	0.50	0.46	0.36	0.46	0.53	0.62	0.61
Income, $m
Income, $m	Revenue	275	319	319	340	321	431	512	512	573	568
	Gross margin, %	66.71	73.63	73.63	73.27	72.71	70.25	64.65	64.06	67.72	68.33
	EBT	(6)	6	6	10	16	9	(189)	(121)	(52)	26
	EBT margin, %	(2.06)	1.91	1.91	2.85	4.96	2.20	(36.91)	(23.64)	(9.13)	4.53
	Net income	(7)	0	(12)	6	15	10	(213)	(196)	(47)	27
	Depreciation	—	0	31	30	29	35	55	57	50	47
Per share, $
Per share, $	Revenue	4.83	65.14	65.14	5.99	5.65	9.48	8.34	8.18	8.88	8.53
	Earnings	(0.41)	(2.49)	(2.49)	(0.01)	0.89	(0.15)	(2.59)	(2.49)	(0.52)	0.34
	Cash flow	0.65	0.00	9.22	0.72	1.26	0.51	(0.22)	0.24	0.60	1.12
	Capex	0.00	0.00	(0.52)	(0.04)	(0.29)	(0.30)	(0.02)	(0.12)	(0.02)	(0.04)
	Free cash flow	0.65	0.00	8.70	0.68	0.97	0.21	(0.24)	0.13	0.59	1.08
	Book value	0.00	0.00	0.00	2.56	2.54	11.74	6.71	3.53	2.88	3.43
	Shares, m	57	5	5	57	57	45	61	63	65	67
Valuation, ×
Valuation, ×	P/E	21.92	21.92	21.92	21.92	21.92	32.43	0.00	0.00	0.00	21.88
	P/S	0.29	0.29	0.29	0.29	0.29	1.53	0.31	0.64	1.18	0.87
	P/B	0.65	0.65	0.65	0.65	0.65	1.23	0.39	1.49	3.65	2.17
	EV/Sales	0.61	0.61	0.61	0.61	0.61	2.25	1.07	1.34	1.70	1.30
	EV/FCF	2.89	2.89	2.89	2.89	2.89	102.14	(36.50)	86.04	25.72	10.24
Cash, $m
Cash, $m	Operating cash flow	37	0	45	41	72	23	(14)	15	39	75
	Capex	—	0	(3)	(2)	(17)	(14)	(1)	(7)	(1)	(3)
	Free cash flow	37	0	43	38	55	9	(15)	8	38	72
Balance, $m
Balance, $m	Working capital	—	—	83	94	89	82	(31)	93	65	112
	Total debt	—	—	195	198	188	358	418	395	336	294
	Net debt	—	—	152	133	102	308	388	358	294	243
	Shareholders’ equity	—	—	—	146	144	534	412	221	186	228
Returns, %
Returns, %	ROA	0.00	(8.12)	0.00	2.90	3.39	2.25	(12.21)	(14.31)	(4.70)	3.22
	ROIC	—	0.00	10.49	6.99	5.40	0.89	(13.06)	(8.82)	(1.98)	7.16
	ROE	0.00	0.00	(12.49)	4.71	11.33	5.72	(33.55)	(49.34)	(17.76)	10.98

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BVS Bioventus Inc.	$1.2B	16.4×	21.4×	+3.76% (above 0%: growing)	+345.45% (above 0%: growing)	−25.11% (below 0%: shrinking)	68.97%	12.48%
TNDM Tandem Diabetes Care, Inc.	$1.2B	— (loss-making)	— (loss-making)	+5.77% (above 0%: growing)	n/m	−146.34% (below 0%: shrinking)	56.87%	(5.42%)	Compare
IRMD iRadimed Corporation	$1.1B	48.5×	48.7×	+0.28% (above 0%: growing)	−8.89% (below 0%: shrinking)	+11.66% (above 0%: growing)	74.07%	31.23%	Compare
ENOV Enovis Corporation	$1.1B	— (loss-making)	195×	+3.23% (above 0%: growing)	n/m	+815.79% (above 0%: growing)	61.64%	2.99%	Compare
AORT Artivion, Inc.	$1.1B	— (loss-making)	142×	+11.32% (above 0%: growing)	n/m	−202.47% (below 0%: shrinking)	64.03%	(6.65%)	Compare
CBLL CeriBell, Inc.	$1.1B	— (loss-making)	— (loss-making)	+32.54% (above 0%: growing)	n/m	−68.63% (below 0%: shrinking)	92.32%	(71.11%)	Compare
IART Integra LifeSciences Holdings Corporation	$1.1B	— (loss-making)	26.1×	+0.76% (above 0%: growing)	n/m	+193.48% (above 0%: growing)	52.47%	4.61%	Compare
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)	Compare
Median of peers	$1.1B	—	48.7×	+6.80%	—	−6.38%	62.84%	(1.21%)

All 149 Medical Devices stocks →

Bioventus Inc. (BVS) key facts

Concern: Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024.
Bioventus Inc. (BVS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BVS traded at $13.30, a market capitalization of $1.2 billion.
Return on equity was 11.0% and debt-to-equity 0.90.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 1.26 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.